Therapeutic Insights
Filter News
Found 146 articles
-
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
-
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ...
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
-
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
-
What is the best way to prevent or even reverse Alzheimer’s disease? That’s the question at the top of many researchers’ minds, especially given all of the recent large Phase 3 failures involving beta-amyloid targeting drugs, the most pursued target to date. This is troubling but not entirely sho...
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Alzheimer’s Breakthrough: C2N First to Offer a Widely Accessible Blood Test
10/29/2020
Alzheimer’s Breakthrough: C 2 N First to Offer a Widely Accessible Blood Test PrecivityAD TM Blood Test Answers Calls from Patients, Advocates, and Physicians Who Want Earlier Answers
-
vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event
10/29/2020
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will make an oral presentation at the 13 th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event on November 4, 2020. The presentation will provide a general study update and data on the baseline characteristics of patients enrolled in the ongoing phase 2 Elevage Study of azeliragon as a potential treatment for mild-probable Alzheimer’s disease (AD) in adult patients who a
-
Titan Medical Announces Achievement of $10 Million Technical Milestone Under Medtronic Development and License Agreement
10/26/2020
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed the first technical milestone under the development and license agreement with Medtronic plc (“Medtronic”) (NYSE: MDT), and is due to receive a U.S. $10 million payment. The development and l
-
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
10/26/2020
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13 th Clinical Trials on Alzheimer's Disease (CTAD) Conference
-
HFC Raises Over $325K and Connects Over 2000 Supporters for Alzheimer's Awareness During First Virtual Game Show, Hosted by Seth Rogen
10/23/2020
National Alzheimer's Nonprofit Takes Annual Fundraising Virtual With Celebrity-Hosted, 70s-Themed Game Show Featuring Elizabeth Banks, Anna Faris, Jim Gaffigan, Billy Eichner and Craig Robinson.
-
Amylyx Pharmaceuticals Announces Publication of CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS
10/16/2020
Data From CENTAUR Trial Published in Muscle & Nerve Demonstrates That Administration of AMX0035 Results in Longer Survival for People With ALS Early Administration of AMX0035 Reduced the Risk of Death by 44% Over the Duration of Follow-Up AMX0035 is the First ALS Therapeutic to Demonstrate Both a Statistically Significant Survival and Functional Benefit in ALS in a Randomized Controlled Trial
-
Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's Disease
10/1/2020
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in the company’s Phase 2/3 clinical trial evaluating ATH-1017, a once-daily investigational drug for the trea
-
Cassava Sciences’ Phase 2b Clinical Results in Alzheimer’s Selected as Late-Breaking News at CTAD 2020
9/30/2020
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that clinical results of its Phase 2b study of sumifilam have been selected as a late-breaking oral presentation by the 13 th international conference on Clinical Trials on Alzheimer’s Disease (CTAD). CTAD is a prestigious annual conference focused on Alzheimer’s research and development and takes place this year as
-
Avacta Launches SARS-CoV-2 BAMS Research Test
9/30/2020
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION™ platforms, is pleased to announce that the BAMS™ assay to detect the SARS-CoV-2 virus has been launched as a research kit 1 by its partner Adeptrix (Beverly, M
-
Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients
9/24/2020
Cortexyme, Inc. (Nasdaq: CRTX) today announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme’s lead investigational medicine, in patients with mild to mode
-
The drug failed to meet its primary efficacy endpoint, as well as two secondary endpoints.
-
Ground-Breaking Alzheimer's Study Administers First Dose
9/22/2020
AHEAD Study, the first trial that aims to help prevent Alzheimer's disease, is recruiting participants as young as 55 at risk for dementia and using a new personalized medicine approach Study launched during World Alzheimer's Month [22-September-2020] SAN DIEGO , Sept. 22, 2020 /PRNewswire/ -- The first infusion of an investigational drug that aims to delay
-
ProMIS Neurosciences to develop multivalent vaccine for Alzheimer’s diseasePotential vaccine to incorporate ProMIS proprietary peptide antigens; early in vivo preclinical data demonstrate neuronal protection and improvement in cognitive deficits
9/22/2020
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today initiation of a program to construct and test a multivalent peptide vaccine for Alzheimer’s disease (AD). The critical first steps in vaccine development will be carried out by VIDO-Inte